Leaf-casting machine for treating imperfections

You can find this article in the article group: Leaf-casting, imperfection & replenishment machines, Paper restoration
ArchivareRestorers

Item description:

Multifunctional partial stabilisation and leaf casting for treating imperfections on paper and printed works.

Assembly and equipment of the leaf-casting machine

The processing tank is made of stainless steel and polished electromechanically. This makes it easy to clean and resistant to chemicals. The base features LED lighting for optimum working. The leaf-casting tank is equipped with 2 linear lifting cylinders for even lifting of paper surface (perforated plate). A folding frame fixes the book pages to be processed. The lateral overflow tank features a pump which supplies the prepared, water-based solution to the book pages via a distribution system.

Measurements and size
  • Usable area: 750 x550 mm
  • Depth approx. : 680 mm
  • Width approx. : 1,600 mm
  • Height approx. : 950/1,400 mm
  • Storage capacity
  • Leaf-casting tank: 150 l
  • Storage capacity
  • Overflow tank: 50 l
  • Version with lateral tank: left
Materials
  • Treatment basins: Stainless steel
  • Frame construction: Aluminium
  • Frame construction: Aluminium
  • LED light sight glass: sodium silicate opt. borosilicate glass Borosilikatglas
buch_4

Dear Sir or Madam,
Dear Mr Weinert,
27.04.2021


On April 30, 2021, we will open another site at Allergopharma GmbH & Co. KG in Reinbek to support COVID 19 vaccine production in the presence of Federal Minister Spahn and Minister President Günther. We would have been pleased to invite you to this opening.

Unfortunately, this was not possible due to the pandemic.
We would therefore like to take this opportunity to thank you for your extraordinary commitment to supplying equipment at short notice to support vaccine production. Allergopharma, as part of Dermapharm Holding SE, is now a further partner in the Europe-wide production network for the vaccine of BioNTech and Pfizer. This network now comprises more than a dozen important pharmaceutical manufacturers and suppliers. From now on, one of four production steps will take place in Reinbek: the vaccine formulation. This is where our mRNA active ingredient is combined with the lipids. A protective shell is created around the mRNA and the vaccine can reach its target in the body to induce the necessary immune response.


Your company has made a very important contribution to the global pandemic response with great know-how and under incredible time pressure. We would like to express our sincere thanks to you and your team! Without their commitment, the successful completion of the project would not have been possible.
We look forward to working with you in partnership in the future!

Dr. Hans-Georg Feldmeier – CEO Dermapharm SE
Dr. Sierk Poetting – CFO and COO BioNTech SE